Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Replagal in Chinese Treatment-Naïve Fabry Disease Patients
CTR20220105Phase 3Completed
- Sponsor
- Takeda
- Start
- Jan 2022
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of agalsidase alfa in Fabry disease (FD), sponsored by Takeda. Started Jan 2022; status: completed.
02
Drugs
agalsidase alfa
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on CTR20220105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220105.